# US 2011/0257077 A1 · Compounds and compositions as channel activating protease inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0257077 A1
- Document ID: US20110257077A1
- Status: Published application
- Kind: A1
- Application number: 13/089,973
- Filed: 2011-04-19
- Published: 2011-10-20
- Earliest claimed: 2006-05-23
- Assignees: Irm LLC
- Inventors: David C. Tully; Amab K. Chatterjee; Agnes Vidal; Hank Michael James Petrassi; Zhiwei Wang; Badry Bursulaya; Glen Spraggon
- Web page: https://patentgrep.com/patent/US20110257077A1

## CPC

- C07D 417/14: containing three or more hetero rings
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07K 5/0806: {the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala}
- C07K 5/0808: {the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu}
- C07K 5/0812: {and aromatic or cycloaliphatic}
- C07K 5/0821: {with the first amino acid being heterocyclic, e.g. His, Pro, Trp}
- C07K 5/0827: {containing heteroatoms different from O, S, or N}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.

## Claims

### Claim 1

A compound of Formula (1):
or pharmaceutically acceptable salts, hydrates, solvates and stereoisomers thereof, wherein:
J is a 5-12 membered monocyclic or fused carbocyclic ring, aryl, heteroaryl or heterocyclic ring containing N, O and/or S;
R1 is —(CR2)l—NR2, —(CR2)l—NRC(═NR)—NR2, —(CR2)l—C(═NR)—NR2 or a 5-7 membered nitrogen-containing non-aromatic heterocyclic ring;
W—R2 is a substituent at any position on ring A;
W is —O(CR2)k—, —S(CR2)k—, —S(O)(CR2)k—, —SO2(CR2)k— or —OC(O)(CR2)k—;
R2 is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, R8, —CR10═CR10—R8, or
wherein ring E is an optionally substituted 5-7 membered monocyclic or fused carbocyclic or heterocyclic ring; or W—R2 together form C1-6 alkyl, aryl or
—OC(O)NR6R7;
Y is —(CO)—NR—R3, —(CO)—O—R3, or C1-6 alkyl;
R3 is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, —(CR2)l—C3-7cycloalkyl or —(CR2)l—R8;
R4 is H, C1-6 alkyl, C2-6 alkenyl, —CR10═CR10—R8, —CR[(CR2)l—R8]2, C2-6 alkynyl, —O—(CR2)l—R9, NR6R7,
or an optionally substituted 5-7 membered carbocyclic ring, heterocyclic ring, aryl or heteroaryl; or R4 together with Y form an optionally substituted 5-12 membered non-aromatic heterocyclic ring;
R5 is halo, C1-6 alkyl, C1-6 alkoxy, OR9 or R9;
R6 and R7 are independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl or —(CR2)l—R8; or R6 and R7 together with N may form an optionally substituted 5-7 membered monocyclic or fused heterocyclic ring;
X, R8 and R9 are independently an optionally substituted 5-7 membered carbocyclic ring, heterocyclic ring, aryl or heteroaryl; or R9 may be H or C1-6 alkyl;
R10 is H or C1-6 alkyl;
each R is H, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl;
i is 0-1,
k, l and m are independently 0-6;
n is 1-6; and
p is 0-3.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 is —(CH2)l—NH2, —(CH2)l—NHC(═NH)—NH2 or —(CH2)l—C(═NH)—NH2, wherein each l is 0-1; or R1 is piperidinyl.

### Claim 3 (depends on 1)

The compound of claim 1, wherein W is —O(CR2)k—, —S(CR2)k—, —S(O)(CR2)k—, —SO2(CR2)k— or —OC(O)(CR2)k—; and k is 1.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R2 is an optionally substituted phenyl, thienyl, C5-7 cycloalkyl, furanyl, piperidinyl, methylenecyclohexyl,

### Claim 5 (depends on 1)

The compound of claim 1, wherein Y is —(CO)—NH—R3 or —(CO)—O—R3; R3 is C1-6 alkyl, —(CR2)l-cyclopropyl or —(CR2)l—R8 wherein R8 is an optionally substituted phenyl.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R4 is H, C1-6 alkyl, C2-6 alkenyl, —NH2, or an optionally substituted phenyl, phenoxy, piperidinyl, C5-7 cycloalkyl, cyclohexanol, imidazolyl, thienyl,
or R4 together with Y form an optionally substituted pyrrolidinyl, pyrrolidinonyl, tetrahydroisoquinolinyl or tetrahydronapthalenyl.

### Claim 7 (depends on 1)

The compound of claim 1, wherein -J-(R5)p together is
Z is O or S;
Z1, Z2, Z3 or Z4 are independently N, CH, or C when attached to R5;
Z5, Z6 or Z7 are independently N, O, S, CH, or C when attached to R5;
p is 0-1; and
R5 is halo or C1-6 alkyl.

### Claim 8 (depends on 1)

The compound of claim 1, wherein R8 is an optionally substituted phenyl, C5-7 cycloalkyl, piperidinyl, cyclohexanol, imidazolyl, thienyl or furanyl.

### Claim 9 (depends on 1)

The compound of claim 1, wherein i is 1; and X is an optionally substituted cyclohexyl, phenyl or piperidinyl.

### Claim 10 (depends on 1)

The compound of claim 1, wherein J is benzothiazolyl, benzoxazolyl, thiazolyl, or oxadiazolyl.

### Claim 11 (depends on 1)

The compound of claim 1, wherein said compound has Formula (2A) or (2B):
wherein Z is O or S;
R1 is NH2, —NHC(═NH)—NH2 or —C(═NH)—NH2;
W is —O(CH2)k— or —S(O)(CH2)k—;
R2 is an optionally substituted phenyl, or W—R2 together form C1-6 alkyl or an optionally substituted phenyl;
Y is —(CO)—O—R3;
R3 is C1-6 alkyl, —(CH2)l-cyclopropyl or —(CH2)l—R8 wherein R8 is an optionally substituted phenyl;
R4 is an optionally substituted, phenyl, piperidinyl, C5-7 cycloalkyl, cyclohexanol, imidazolyl, thienyl,
i and p are 0;
k is 1;
l is 0-1; and
m and n are independently 1-4.

### Claim 12 (depends on 11)

The compound of claim 11, wherein R4 is piperidinyl.

### Claim 13 (depends on 1)

The compound of claim 1, wherein said compound has Formula (3A) or (3B):
wherein R6 and R7 independently H, C1-6 alkyl or —(CR2)l—R8; or R6 and R7 together with N form an optionally substituted pyrrolidinyl, piperidinyl, morpholino, piperazinyl or diazepanyl;
R8 is an optionally substituted phenyl, furanyl, tetrahydrofuranyl, piperidinyl or thienyl; and
i and p are 0.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable excipient.

### Claim 15

A method for modulating a channel activating protease, comprising administering to a cell, tissue or a subject in need thereof, a therapeutically effective amount of the compound of a compound of Formula (1):
or pharmaceutically acceptable salts, hydrates, solvates and stereoisomers thereof, wherein:
J is a 5-12 membered monocyclic or fused carbocyclic ring, aryl, heteroaryl or heterocyclic ring containing N, O and/or S;
R1 is —(CR2)l—NR2, —(CR2)l—NRC(═NR)—NR2, —(CR2)l—C(═NR)—NR2 or a 5-7 membered nitrogen-containing non-aromatic heterocyclic ring;
W—R2 is a substituent at any position on ring A;
W is —O(CR2)k—, —S(CR2)k—, —S(O)(CR2)k—, —SO2(CR2)k— or —OC(O)(CR2)k—;
R2 is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, R8, —CR10═CR10—R8, or
wherein ring E is an optionally substituted 5-7 membered monocyclic or fused carbocyclic or heterocyclic ring; or W—R2 together form C1-6 alkyl, aryl or
—OC(O)NR6R7;
Y is SO2R3, —(CO)—NR—R3, —(CO)—O—R3, SO2NR6R7 or C1-6 alkyl;
R3 is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, —(CR2)l—C3-7cycloalkyl or —(CR2)l—R8;
R4 is H, C1-6 alkyl, C2-6 alkenyl, —CR10═CR10—R8, —CR[(CR2)l—R8]2, C2-6 alkynyl, —O—(CR2)l—R9, NR6R7,
or an optionally substituted 5-7 membered carbocyclic ring, heterocyclic ring, aryl or heteroaryl; or R4 together with Y form an optionally substituted 5-12 membered non-aromatic heterocyclic ring;
R5 is halo, C1-6 alkyl, C1-6 alkoxy, OR9 or R9;
R6 and R7 are independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl or —(CR2)l—R8; or R6 and R7 together with N may form an optionally substituted 5-7 membered monocyclic or fused heterocyclic ring;
X, R8 and R9 are independently an optionally substituted 5-7 membered carbocyclic ring, heterocyclic ring, aryl or heteroaryl; or R9 may be H or C1-6 alkyl;
R10 is H or C1-6 alkyl;
each R is H, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl;
i is 0-1,
k, l and m are independently 0-6;
n is 1-6; and
p is 0-3;
or pharmaceutical compositions thereof, thereby modulating said channel activating protease;
wherein said channel activating protease is prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.

### Claim 16 (depends on 15)

The method of claim 15, wherein said subject is a human or animal subject.

### Claim 17 (depends on 15)

The method of claim 15, wherein said cell is bronchial epithelial cell.

### Claim 18

A method for ameliorating a condition mediated by a channel activating protease, comprising administering to a subject in need of such treatment an effective amount of a compound of Formula (1):
or pharmaceutically acceptable salts, hydrates, solvates and stereoisomers thereof, wherein:
J is a 5-12 membered monocyclic or fused carbocyclic ring, aryl, heteroaryl or heterocyclic ring containing N, O and/or S;
R1 is —(CR2)l—NR2, —(CR2)l—NRC(═NR)—NR2, —(CR2)l—C(═NR)—NR2 or a 5-7 membered nitrogen-containing non-aromatic heterocyclic ring;
W—R2 is a substituent at any position on ring A;
W is —O(CR2)k—, —S(CR2)k—, —S(O)(CR2)k—, —SO2(CR2)k— or —OC(O)(CR2)k—;
R2 is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, R8, —CR10═CR10—R8, or
wherein ring E is an optionally substituted 5-7 membered monocyclic or fused carbocyclic or heterocyclic ring; or W—R2 together form C1-6 alkyl, aryl or
—OC(O)NR6R7;
Y is SO2R3, —(CO)—NR—R3, —(CO)—O—R3, SO2NR6R7 or C1-6 alkyl;
R3 is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, —(CR2)l—C3-7cycloalkyl or —(CR2)l—R8;
R4 is H, C1-6 alkyl, C2-6 alkenyl, —CR10═CR10—R8, —CR[(CR2)l—R8]2, C2-6 alkynyl, —O—(CR2)l—R9, NR6R7,
or an optionally substituted 5-7 membered carbocyclic ring, heterocyclic ring, aryl or heteroaryl; or R4 together with Y form an optionally substituted 5-12 membered non-aromatic heterocyclic ring;
R5 is halo, C1-6 alkyl, C1-6alkoxy, OR9 or R9;
R6 and R7 are independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl or —(CR2)l—R8; or R6 and R7 together with N may form an optionally substituted 5-7 membered monocyclic or fused heterocyclic ring;
X, R8 and R9 are independently an optionally substituted 5-7 membered carbocyclic ring, heterocyclic ring, aryl or heteroaryl; or R9 may be H or C1-6 alkyl;
R10 is H or C1-6 alkyl;
each R is H, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl;
i is 0-1;
k, l and m are independently 0-6;
n is 1-6; and
p is 0-3;
or pharmaceutical compositions thereof, and optionally in combination with a second therapeutic agent, thereby treating said condition;
wherein said channel activating protease is prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase; and
wherein said second therapeutic agent is an anti-inflammatory, bronchodilatory, antihistamine, anti-tussive, antibiotic or DNase.

### Claim 19 (depends on 18)

The method of claim 18, wherein said channel activating protease is prostasin or matriptase (MTSP-1).

### Claim 20 (depends on 18)

The method of claim 18, wherein said condition is associated with the movement of fluid across ion transporting epithelia or the accumulation of mucus and sputum in respiratory tissues, or a combination thereof; or wherein said condition is cystic fibrosis, primary ciliary dyskinesia, lung carcinoma, chronic bronchitis, chronic obstructive pulmonary disease, asthma or a respiratory tract infection.
